We are live on ! Find out more
ALXO icon

ALX Oncology
ALXO

86 hedge funds and large institutions have $161M invested in ALX Oncology in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,900% more call options, than puts

Call options by funds: $80K | Put options by funds: $1K

24% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 25

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

1% less funds holding

Funds holding: 87 → 86 (-1)

2.02% less ownership

Funds ownership: 89.39% → 87.37% (-2%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

61% less capital invested

Capital invested by funds: $410M → $161M (-$248M)

Holders
86
Holders Change
-1
Holders Change %
-1.15%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
11
Increased
31
Reduced
25
Closed
12
Calls
$80K
Puts
$1K
Net Calls
+$79K
Net Calls Change
-$146K

Top Buyers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
+$7.51M
2
Citadel Advisors
Citadel Advisors
Florida
+$769K
3
HF
HRT Financial
New York
+$625K
4
Squarepoint
Squarepoint
New York
+$479K
5
Two Sigma Investments
Two Sigma Investments
New York
+$472K

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$6.44M
2
PC
Pier Capital
Connecticut
-$3.06M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$2.95M
4
EAM
Eventide Asset Management
Massachusetts
-$1.8M
5
Bank of America
Bank of America
North Carolina
-$1.35M
Name Holding Trade Value Shares
Change 		Change in
Stake
VP
1
venBio Partners
California
$43.8M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$27.7M +$121K +16,013 +0.3%
VC
3
Vivo Capital
California
$19.1M – – –
O
4
OrbiMed
New York
$13M – – –
BlackRock
5
BlackRock
New York
$7.54M -$246K -32,462 -2%
LGM
6
Logos Global Management
California
$6.78M -$6.44M -849,600 -36%
B
7
Braidwell
Connecticut
$5.65M +$7.51M +991,620 +384%
Vanguard Group
8
Vanguard Group
Pennsylvania
$4.68M -$2.95M -389,759 -27%
EAM
9
Eventide Asset Management
Massachusetts
$3.01M -$1.8M -237,171 -26%
CAM
10
Cormorant Asset Management
Massachusetts
$2.77M – – –
RG
11
Redmile Group
California
$2.65M -$155K -20,493 -3%
Federated Hermes
12
Federated Hermes
Pennsylvania
$2.31M +$353K +46,637 +10%
AG
13
Artal Group
Luxembourg
$2.26M – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.9M +$66.2K +8,735 +2%
State Street
15
State Street
Massachusetts
$1.78M +$2.98K +394 +0.1%
Deutsche Bank
16
Deutsche Bank
Germany
$1.57M +$33.6K +4,434 +1%
Morgan Stanley
17
Morgan Stanley
New York
$1.42M -$1.3M -172,132 -35%
SB
18
Samsara BioCapital
California
$1.19M – – –
Citadel Advisors
19
Citadel Advisors
Florida
$1.1M +$769K +101,533 +72%
Northern Trust
20
Northern Trust
Illinois
$897K -$33.1K -4,374 -2%
Goldman Sachs
21
Goldman Sachs
New York
$817K +$39.3K +5,186 +3%
Charles Schwab
22
Charles Schwab
California
$680K -$72.1K -9,513 -6%
Los Angeles Capital Management
23
Los Angeles Capital Management
California
$649K -$48.7K -6,425 -4%
Renaissance Technologies
24
Renaissance Technologies
New York
$573K +$235K +31,019 +32%
Two Sigma Advisers
25
Two Sigma Advisers
New York
$542K +$259K +34,200 +40%
1
2 3 4

ALXO Hedge Fund Activity: Q1 2023 in Review

86 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q1 2023, worth a combined $161M — down 61% from $410M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ALXO and 11 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 31 added.

The largest buyer was Braidwell, adding an estimated $7.51M. The largest seller was Logos Global Management, cutting an estimated $6.44M.

  • 86 institutional investors held ALX Oncology (ALXO) as of Q1 2023, down from 87 in Q4 2022.
  • Funds reported $161M of ALX Oncology stock for Q1 2023, down 61% quarter-over-quarter.
  • 11 funds opened new ALX Oncology positions in Q1 2023 and 12 closed out, a net change of -1 holder.
  • The largest ALX Oncology buyer in Q1 2023 was Braidwell, an estimated $7.51M added.
  • The largest ALX Oncology seller in Q1 2023 was Logos Global Management, an estimated $6.44M sold.

Based on aggregated 13F filings for Q1 2023.